Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)

BACKGROUND: A randomized trial of vinorelbine plus gemcitabine followed by docetaxel (VGD) versus paclitaxel plus carboplatin (PC) in patients with advanced non-small-cell lung cancer showed no difference in overall survival (median survival time: 13.6 versus 14.1 months) between the two treatment g...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Masaaki, Tada, Harue, Tokoro, Akihiro, Teramukai, Satoshi, Origasa, Hideki, Kubota, Kaoru, Shinkai, Tetsu, Fukushima, Masanori, Furuse, Kiyoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179458/
https://www.ncbi.nlm.nih.gov/pubmed/21849041
http://dx.doi.org/10.1186/1471-2407-11-356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179458/
https://www.ncbi.nlm.nih.gov/pubmed/21849041
http://dx.doi.org/10.1186/1471-2407-11-356

Ejemplares similares